Table 1 Comparison of the clinicopathological factors between patients with high and low microvessel densities (MVDs) following hepatic resection of intrahepatic cholangiocarcinoma.

From: Prognostic impact of tumor microvessels in intrahepatic cholangiocarcinoma: association with tumor-infiltrating lymphocytes

Factors

High MVD (n = 50)

Low MVD (n = 50)

P value

Age (years)

65 (33–82)

67 (39–87)

0.424

Sex (male/female)

35/15

33/17

0.668

HBV (+, %)

4 (8.0%)

6 (12.0%)

0.505

HCV (+, %)

5 (10.0%)

5 (10.0%)

1.000

Albumin (g/dL)

4.1 (3.2–5.3)

4.1 (2.9–4.7)

0.729

Total bilirubin (mg/dL)

0.7 (0.2–1.8)

0.7 (0.4–8.7)

0.637

ALP (U/L)

307.0 (127–1344)

351.5 (125–1337)

0.143

γ-GTP (IU/L)

76.5 (24–574)

94.5 (11.7–1071)

0.508

Platelets (×104/μL)

13.3 (5.2–44.0)

21.6 (10.4–54.3)

0.017*

Total lymphocytes (×103/uL)

1.5 (0.4–4.0)

1.4 (0.4–2.8)

0.391

ICG15 (%)

11.6 (1.9–31.0)

9.1 (2.3–23.6)

0.179

CEA (ng/mL)

2.8 (0.0–117.5)

2.6 (0.4–30.7)

0.664

CA19-9 (U/mL)

34.9 (0.0–531.9)

90.4 (0.6–98106)

0.008*

Tumor size (cm)

3.5 (0.5–12.0)

5.0 (1.7–9.5)

0.016*

Tumor localization (peripheral type/perihilar type)

40/10

32/18

0.075

ICC subtype (n = 72)

MF/PI/IG

38/2/0

29/2/1

0.426

Poor differentiation (%)

27 (54.0%)

32 (64.0%)

0.309

Microvascular invasion (%)

18 (36.0%)

34 (68.0%)

0.001*

Bile duct invasion (%)

19 (38.0%)

23 (46.0%)

0.418

Intrahepatic metastasis (%)

13 (26.0%)

24 (48.0%)

0.023*

Lymph node metastasis (%)

4 (8.0%)

19 (38.0%)

<0.001**

Histological liver cirrhosis (%)

7 (14.0%)

4 (8.0%)

0.338

  1. Data are presented as n (%) or the median (range).
  2. ALP alkaline phosphatase, CA19-9 carbohydrate antigen 19-9, CEA carcinoembryonic antigen, γ-GTP γ-glutamyl transpeptidase, HBV hepatitis B virus, HCV hepatitis C virus, ICG15 indocyanine green retention rate at 15 min, IG intraductal growth, MF mass-forming, MVD microvessel density, PI periductal infiltrating.
  3. *P < 0.05; **P < 0.001.